Financial Results Briefing for Q2 FY2025
We Bring New Hope to Life
August 29, 2025
Securities Code: TSE:2160
GNI Group Overview
Global Expansion
A global biopharmaceutical company (TSE: 2160) that leverages the Chinese and U.S. markets to achieve sustainable business growth from its headquarters in Japan
Business Composition
① Pharmatech ② Biotech ③ Medtech
Priority disease areas: fibrosis, pain, cancer, orthopedics
Grobal Network
Major geographical operations : Japan, PRC, U.S., Australia Subsidiaries and affiliates：26
Number of employees ：915
R&D and Sales
Structured R&D pipeline and marketed products：23 Hospitals and pharmacies in PRC：3,000
Comprehensive sales ：400
Acceleration of Group Growth through a Strategic Global Structure
GNI Group has established a unique position within the healthcare value chain spanning China, the United States, and Japan. By achieving a strategic balance among Innovation, Operational Efficiency, and Strategic Agility on a global scale, the Group maximizes its complementary strengths to their fullest potential.
Japan
Headquarters and GNI Group's listing venue (2160.T)
To build a globally coordinated innovation engine by fostering deeper collaboration
Creation of synergies through the reinforcement of strategic collaboration among Group companies
PRC
Established sales and marketing team with successful commercialization track record
POC trials in PRC to optimize time and cost efficiency
GMP-compliant manufacturing facilities
US
Listing venue of Gyre Therapeutics (Nasdaq:GYRE)
Cullgen, scheduled for listing (Nasdaq: PULM)
MedTech hub for biomaterials sales, R&D, and manufacturing
Through this trilateral structure, the Group has built an integrated value chain spanning R&D, manufacturing, and sales, enabling efficient business development by leveraging regional strengths. The Group aims to maximize investment efficiency while establishing a sustainable competitive advantage in the global market.
Management by experienced leadership that leverages the delegation of authorityGroup Pharma Biotech Medtech
Ying Luo, Ph.D.
President & CEO
Ryosuke Matsui Vice President COO & CFO
Ping Zhang
Executive Officer
Ping Zhang
Executive Chairman & Interim CEO
Weiguo Ye
COO
Ruoyu Chen
CFO
Ying Luo, Ph.D.
Chairman & CEO
Yue Xiong, Ph.D.
Founder & CSO
Thomas Eastling
CFO
Danielle Kelley
CEO
Mesfin Mengesha, M.D.
President
David Miao, CPA, MBA
Interim CFO
Financial Highlights